Stay updated on Lazertinib vs Intravenous Amivantamab in Lung Cancer Clinical Trial

Sign up to get notified when there's something new on the Lazertinib vs Intravenous Amivantamab in Lung Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Lazertinib vs Intravenous Amivantamab in Lung Cancer Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    A sitewide NIH notice about a terminology transition appears above the ClinicalTrials.gov 403 error page, and the site revision advances from v3.7.1 to v3.7.2.
    Difference
    1%
    Check dated 2026-10-20T22:01:10.000Z thumbnail image
  2. Check
    11 days ago
    No Change Detected
  3. Check
    18 days ago
    Change Detected
    Summary
    The site revision identifier in the footer changes from v3.7.0 to v3.7.1 on the 403 error page.
    Difference
    0.2%
    Check dated 2026-10-06T22:24:04.000Z thumbnail image
  4. Check
    32 days ago
    Change Detected
    Summary
    The study page now displays a 403 Forbidden error with a Home link, replacing the previously loaded study content and related links. This indicates the page is currently inaccessible rather than showing study details.
    Difference
    16%
    Check dated 2026-09-23T00:20:57.000Z thumbnail image
  5. Check
    39 days ago
    Change Detected
    Summary
    A new page revision, v3.7.0, has been published, replacing the previous v3.6.6. This reflects an update to the page's revision history rather than a change to substantive content.
    Difference
    0.0%
    Check dated 2026-09-16T00:20:14.000Z thumbnail image
  6. Check
    53 days ago
    Change Detected
    Summary
    Revision history on the page was updated with new August 2026 entries. A new Revision: v3.6.6 supersedes the previous Revision: v3.6.5.
    Difference
    0.1%
    Check dated 2026-09-01T19:44:05.000Z thumbnail image
  7. Check
    60 days ago
    Change Detected
    Summary
    A new publication citation by Leighl NB et al. was added to the Publications section. The citation describes a plain-language summary of subcutaneous versus intravenous amivantamab plus lazertinib in EGFR-mutated NSCLC and notes that it is online ahead of print.
    Difference
    0.0%
    Check dated 2026-08-25T19:47:04.000Z thumbnail image

Stay in the know with updates to Lazertinib vs Intravenous Amivantamab in Lung Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Lazertinib vs Intravenous Amivantamab in Lung Cancer Clinical Trial page.